Skip to main content
. 2021 Oct 21;13(21):5284. doi: 10.3390/cancers13215284

Figure 4.

Figure 4

Chronic inhibition of IFN signaling reduced cell proliferation and mesenchymal signature. (A) Representative WB of IFN/STAT1 signaling proteins in WCLs of GSCs treated with ruxolitinib (500 and 1000 nM) for 72 h. Original blots see Figure S9. (B,C) Cell viability and proliferation of GSCs treated with ruxolitinib (25–5000 nM) for 3 days and 5 days. (D,E). Cell proliferation of GSCs treated with ruxolitinib (1 and 5 µM) for 2 weeks. Ruxolitinib-treatment-containing media was changed every 72 h. (F,G) mRNA expression of mesenchymal and IFN genes in GSCs treated with ruxolitinib (5 µM) for 2 weeks. *** p < 0.001, ** p < 0.01, and * p < 0.05 compared to untreated cells.